Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Her2+
•
Breast Cancer, Metastatic
How do you approach treatment of metastatic breast cancer in patients where PIK3CA mutation was detected after progression on both Fulvestrant alone and AI + CDK4/6 inhibitors?
Related Questions
Do you feel comfortable using ribociclib in a patient with metastatic ER+/HER2+ breast cancer who has borderline systolic heart failure from previous HER2 based treatment?
What factors do you use to decide between trastuzumab-deruxtecan and sacituzumab govitecan in HER2-low metastatic breast cancer?
What first line therapy would you give a premenopausal patient with HER-2 positive and ER positive metastatic breast cancer with visceral organ involvement?
How do you approach treatment in a young de novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
Would you consider re-challenging Trastuzumab after resolved grade 2 pneumonitis?
How long would you continue trastuzumab and pertuzumab in a patient with ER+ HER2+ breast cancer with initially osseous involvement treated with ACT-HP and is now in CR by PET for >2 years?
Do you have a preference of denosumab over zoledronic acid in patients with metastatic breast cancer with osseous involvement with normal renal function?
Would you approach a previously strongly ER and PR positive and HER2 1+ breast ductal carcinoma as a triple negative breast cancer if its histology now shows ER 5% PR 0 HER2 0 and it is behaving like a triple negative?
How would you treat a patient with symptomatic and rapidly progressing metastatic HR+, HER2 low breast cancer with PIK3CA WT, ESR1 mutated, TMB high after progression on CDK 4/6 inhibitor, a taxane, and T-DXd?
Is there a role of adding hormonal therapy to fam-trastuzumab deruxtecan in patients with metastatic ER/PR+ HER2 low breast cancer after progressing on aromatase inhibitor and CDK4/6i?
